All In Biotech

Drug Trial Radar · NCT07453888

Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Randomized, Multicenter, Vehicle-Controlled, Double-Masked Phase 3 Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 272 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

272

Planned (sponsor's estimate)

Start

Jul 1, 2026

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Dompé Farmaceutici S.p.AIndustry
Sponsor type
Industry
First posted
Mar 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3, randomized, multicenter, vehicle-controlled, double-masked study to evaluate the efficacy and safety of intranasal cenegermin compared with vehicle control in adult participants with NAION. Approximately 272 participants who meet all eligibility criteria will be randomly assigned in a 1:1 ratio to receive either cenegermin treatment (Group 1) or the vehicle control (Group 2).

Conditions

  • Non-Arteritic Anterior Ischemic Optic Neuropathy

Interventions

  • CenegerminDrug

    Cenegermin is administered intranasally.

  • VehicleOther

    Vehicle spray is administered intranasally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Achievement of ≥ 15 letter increase in Best Corrected Visual Acuity (BCVA), assessed in each individual participant, measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) chartTime frame: Baseline to Week 24

Locations

38 sites in 4 countries. Site status is shown where the registry gives one.

  • Neuro Eye Orbit Institute

    Los Angeles, California · Recruiting

  • David Geffen School of Medicine at UCLA - Ophthalmology

    Los Angeles, California · Not yet recruiting

  • California Orbital Consultants

    Newport Beach, California · Recruiting

  • Stanford Byers Eye Institute

    Palo Alto, California · Recruiting

  • UC Davis Health, Ophthalmology

    Sacramento, California · Recruiting

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • Bascom Palmer Eye Institute, University of Miami School of Medicine

    Miami, Florida · Not yet recruiting

  • Sarasota Retina Institute - Research

    Sarasota, Florida · Recruiting

  • University of South Florida/Ophthalmology

    Tampa, Florida · Recruiting

  • Emory University - Emory Eye Center - Atlanta

    Atlanta, Georgia · Recruiting

  • Northwestern University - Ophthalmology

    Chicago, Illinois · Recruiting

  • University of Illinois at Chicago Eye and Ear Infirmary - Ophthalmology

    Chicago, Illinois · Recruiting

  • Univ. Of Kentucky Clinic Dept of Ophthalmology & Vision Science

    Lexington, Kentucky · Not yet recruiting

  • The Johns Hopkins Hospital (JHH)

    Baltimore, Maryland · Recruiting

  • Tufts Medical Center - Neurology

    Boston, Massachusetts · Recruiting

  • University of Michigan Health - Kellogg Eye Center

    Ann Arbor, Michigan · Recruiting

  • Trinity Health Grand Rapids

    Grand Rapids, Michigan · Recruiting

  • University of Minnesota, Dept of Ophthalmology

    Minneapolis, Minnesota · Recruiting

  • Mayo Clinic - Department of Ophthalmology

    Rochester, Minnesota · Recruiting

  • Washington University School of Medicine in St Louis - Ophthalmology

    St Louis, Missouri · Recruiting

  • UNMC Truhlsen Eye Institute

    Omaha, Nebraska · Recruiting

  • Duke Eye Center - Ophthalmology

    Durham, North Carolina · Recruiting

  • University of Pennsylvania - Ophthalmology

    Philadelphia, Pennsylvania · Recruiting

  • Wills Eye Hospital

    Philadelphia, Pennsylvania · Not yet recruiting

  • Retina Consultants of South Carolina, Charleston Neuroscience Institute- West Ashley (RCA)

    Charleston, South Carolina · Recruiting

  • Neuro Eye Clinical Trials

    Houston, Texas · Recruiting

  • Retina Consultants of Texas - The Woodlands

    The Woodlands, Texas · Recruiting

  • Vision SA - Ophthalmology

    Kent Town, South Australia, Australia · Recruiting

  • Cerulea

    East Melbourne, Victoria, Australia · Recruiting

  • Pusan National University Hospital - Ophthalmology

    Busan, Busan Gwang'yeogsi, South Korea · Recruiting

  • Asan Medical Center - Ophthalmology

    Seoul, Seoul Teugbyeolsi, South Korea · Recruiting

  • Samsung Medical Center - Ophthalmology

    Seoul, Seoul Teugbyeolsi, South Korea · Recruiting

  • Bristol NHS Foundation Trust - Bristol Eye Hospital

    Bristol, United Kingdom · Recruiting

  • Liverpool University Hospitals NHS Foundation Trust - Royal Liverpool University Hospital - St Paul's Eye Unit

    Liverpool, United Kingdom · Recruiting

  • Western Eye Hospital

    London, Greater London, United Kingdom · Recruiting

  • Manchester University NHS Foundation Trust - Manchester Royal Eye Hospital

    Manchester, Greater Manchester, United Kingdom · Recruiting

  • Oxford University Hospital NHS Trust - John Radcliffe Hospital

    Abingdon, Oxfordshire, United Kingdom · Recruiting

  • Sheffield Teaching Hospitals NHS Foundation Trust - Royal Hallamshire Hospital

    York, Sheffield, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.